Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) announced its collaboration with the Plant Protein Innovation Center at the University of Minnesota to advance plant-based protein science. The partnership will leverage Waters’ ACQUITY Premier UPLC System to establish a standard workflow for amino acid analysis, vital for evaluating alternative proteins. With projections showing that plant proteins could secure an 11% market share by 2035, Waters aims to support the transition to healthier and sustainable dietary options while addressing climate change and food security challenges.
Waters Corporation (NYSE:WAT) will host its Q2 2022 financial results conference call on August 2, 2022, at 8:00 a.m. ET. The event will be accessible via a live webcast on Waters' investor relations site, with a replay available until August 16, 2022. Waters, a leader in analytical instruments and software, has been innovating in chromatography and mass spectrometry for over 60 years, employing more than 7,800 people and operating in over 35 countries.
Waters Corporation (NYSE:WAT) has partnered with BioInfra to launch the ASEAN Academy for Bioanalysis in South Korea. This training facility aims to equip scientists with essential bioanalytical skills required for drug discovery and development, addressing the increasing demand for low-cost generic drugs in Southeast Asia. The academy will focus on bioequivalence trials, enhancing the region's scientific competitiveness and pharmaceutical research quality, ultimately benefiting the growing elderly population facing health challenges.
Waters Corporation (NYSE:WAT) introduced the Xevo G3 quadrupole time-of-flight mass spectrometer, boasting up to 10X more sensitivity than its predecessor. The launch, announced at the ASMS 2022 Annual Conference, aims to enhance drug discovery and development. Additionally, the new CONFIRM Sequence app streamlines nucleic acid sequencing confirmation, cutting data review time by 50%. Finally, the integration of a new electrospray ionization source with the SELECT SERIES MRT system enables rapid molecular characterization.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will engage in a fireside chat at the Jefferies 2022 Global Healthcare Conference in New York City on June 8th, 2022, at 4:30 PM EST. Interested investors can access the live webcast via Waters' investor relations website, which will be available for replay for 30 days. Waters has been a leader in analytical instruments for over 60 years, operating in 35 countries with a workforce exceeding 7,800 employees.
Waters Corporation (NYSE: WAT) has inaugurated its latest innovation lab, Immerse™ Delaware, at the University of Delaware's STAR campus. This facility aims to tackle major challenges in the biopharmaceutical industry by fostering collaboration between students, faculty, and industry partners. The lab is a product of a multi-year partnership established in October 2021, focusing on improving biotherapeutic development and manufacturing processes.
Waters Corporation (NYSE: WAT) reported first quarter 2022 sales of $691 million, marking a 13% increase year-over-year and a 16% rise in constant currency. Instrument sales surged 26% in constant currency, driven by strong performance across key product lines. The company achieved a GAAP EPS of $2.62 and a non-GAAP EPS of $2.80, reflecting a 22% increase compared to the previous year. Waters raised its 2022 guidance for sales growth to 7.5% to 9% and non-GAAP EPS to $11.90 to $12.10 amid positive customer feedback for new product launches.
Waters Corporation (NYSE:WAT) will host its 2022 Investor Day on May 19, 2022, starting at 8:45 a.m. ET at the New York Stock Exchange in New York, NY. The event includes presentations by senior management and a Q&A session. A live webcast will be available on Waters’ investor relations website, with a replay offered later. Waters Corporation is a leader in analytical instruments and software, serving various scientific fields for over 60 years, operating in 35 countries, and employing over 7,800 people globally.
Waters Corporation (NYSE:WAT) is set to host a live webcast of its Q1 2022 financial results conference call on May 3, 2022, at 8:00 a.m. Eastern Time. Interested parties can access the live presentation via Waters' investor relations website. A replay will be available until May 17, 2022, at midnight Eastern Time. Waters is renowned for its innovations in chromatography, mass spectrometry, and thermal analysis, with over 7,400 employees operating in 35 countries.
Waters Corporation (NYSE:WAT) has launched the Xevo TQ Absolute, advancing mass spectrometry technology. This new tandem quadrupole mass spectrometer is up to 15X more sensitive in quantifying negatively ionized compounds and 45% smaller than its competitors, using 50% less power and nitrogen. Designed for various analytical laboratories, it aims to enhance productivity and support sustainability goals. Shipments are expected to begin in May.